Miriam is the Programme Manager for the Infrastructure Transitions Research Consortium (ITRC). ITRC is a major EPSRC-funded project (£5 million, 7 universities) aimed at developing a new generation of system simulation models and methods to inform analysis, planning and design of national infrastructure in the energy, transport, water, waste and telecoms sectors and working closely with partners in government and industry.
The ITRC will provide a virtual environment with new methods for analysing performance, risks and interdependencies in which to test strategies for long term investment based on the understanding of how alternative strategies perform with respect to policy constraints such as: reliability and security of supply, cost, carbon emissions in future demographic, economic and technological scenarios in the context of climate change adaptation and mitigation.
Miriam holds BSc and MPhil degrees in Molecular Genetics from the University of Sao Paulo, Brazil, and an MA in Philosophy & Government from the University of Essex. The latter focused on legal, economic and political aspects in academia, industry and government interaction in the production of knowledge and wealth in a global context.
Miriam worked in scientific research at the University of Cambridge and the Sanger Centre (Human Genome Project), before moving into industry at Californian and German biotechnology companies, Stratagene, Affymetrix and Eppendorf. She was later a research fellow at the Innovation, Knowledge & Organisational Networks Unit (IKON) at Warwick Business School, a research project funded by the ESRC/EPSRC/DTI to understand challenges in transdisciplinary networks in biomedical research and development in the UK and the US based on case studies involving more than 100 site visits.
Miriam joined the University of Oxford in 2005 to coordinate DC-THERA, a global32-partner collaborative research bringing together genomics, proteomics bioinformatics and clinical data.
At University College London, she managed their 2 largest European grants at the time, VPH-NoE (12 partners, Euro 8 million) and CHAIN, Collaborative HIV and Anti-HIV Drug Resistance Network (23 partners, Euro 10 million). The VPH NoE focused on new virtual environments for predictive, patient-specific, evidence-based, more effective and safer healthcare and on fostering closer cooperation between ICT, medical device, medical imaging, engineering, pharmaceutical and biotech companies. CHAIN was a large scale integrating project aimed to effectively and durably combat new and existing anti-HIV drug resistance in clinical settings, with a special emphasis on Eastern Europe and in heavily affected resource-poor regions in Africa.
Miriam’s main interest is in participating in initiatives in the forefront of biology-related global enterprises and challenges, and more recently in those that have a strong impact on sustainable social and economic distribution of resources.